Ascendis Pharma A/S Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
Ascendis Pharma A/S (ASND) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of EUR 81.74 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2026-02-11
- Ascendis Pharma A/S increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2025-03-31 was -33.04M EUR.
- Ascendis Pharma A/S increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2024-03-31 was -76.00M EUR, a 220.83% decline year-over-year.
- Ascendis Pharma A/S increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2023-03-31 was 62.90M EUR, a 79.41% decline year-over-year.
- Ascendis Pharma A/S increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2022-03-31 was 305.49M EUR.
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 3 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 6 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 9 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month |
|---|---|---|---|---|
| 2025-12-31 | 81.74M EUR 20-F · filed 2026-02-11 | |||
| 2025-09-30 | 3.22M EUR 6-K · filed 2025-11-12 | |||
| 2025-06-30 | -37.74M EUR 6-K · filed 2025-08-07 | |||
| 2025-03-31 | -33.04M EUR 6-K · filed 2025-05-01 | |||
| 2024-12-31 | 144.61M EUR 20-F · filed 2026-02-11 | |||
| 2024-09-30 | 232.08M EUR 6-K · filed 2025-11-12 | |||
| 2024-06-30 | -139.16M EUR 6-K · filed 2025-08-07 | |||
| 2024-03-31 | -76.00M EUR 6-K · filed 2025-05-01 | |||
| 2023-12-31 | -46.59M EUR 20-F · filed 2026-02-11 | |||
| 2023-09-30 | -4.72M EUR 6-K · filed 2024-11-14 | |||
| 2023-06-30 | -45.58M EUR 6-K · filed 2024-09-03 | |||
| 2023-03-31 | 62.90M EUR 6-K · filed 2024-05-02 | |||
| 2022-12-31 | -37.19M EUR 20-F · filed 2025-02-12 | |||
| 2022-09-30 | 103.94M EUR 6-K · filed 2023-11-07 | |||
| 2022-06-30 | 188.75M EUR 6-K · filed 2023-09-05 | |||
| 2022-03-31 | 305.49M EUR 6-K · filed 2023-04-27 | |||
| 2021-12-31 | -176.84M EUR 20-F · filed 2024-02-07 | |||
| 2021-09-30 | 79.02M EUR 6-K · filed 2022-11-02 | |||
| 2021-06-30 | -214.49M EUR 6-K · filed 2022-08-10 | |||
| 2021-03-31 | -111.72M EUR 6-K · filed 2022-05-11 | |||
| 2020-12-31 | 39.90M EUR 20-F · filed 2023-02-16 | |||
| 2020-09-30 | 191.05M EUR 6-K · filed 2021-11-10 | |||
| 2020-06-30 | -360.21M EUR 6-K · filed 2021-08-27 | |||
| 2020-03-31 | -74.04M EUR 6-K · filed 2021-05-27 | |||
| 2019-12-31 | 312.50M EUR 20-F · filed 2022-03-02 | |||
| 2019-09-30 | 358.60M EUR 6-K · filed 2020-11-12 | |||
| 2019-06-30 | 417.67M EUR 6-K · filed 2020-08-27 | |||
| 2019-03-31 | 415.74M EUR 6-K · filed 2020-05-19 | |||
| 2018-12-31 | 61.82M EUR 20-F · filed 2021-03-10 | |||
| 2018-09-30 | 97.52M EUR 6-K · filed 2019-11-18 | |||
| 2018-06-30 | 142.98M EUR 6-K · filed 2019-08-28 | |||
| 2018-03-31 | 160.06M EUR 6-K · filed 2019-05-30 | |||
| 2017-12-31 | 28.68M EUR 20-F · filed 2020-04-03 | |||
| 2017-09-30 | 36.65M EUR 6-K · filed 2018-11-28 | |||
| 2017-06-30 | -45.11M EUR 6-K · filed 2018-08-29 | |||
| 2017-03-31 | -20.98M EUR 6-K · filed 2018-05-30 | |||
| 2016-12-31 | 56.61M EUR 20-F · filed 2019-04-03 | |||
| 2015-12-31 | 61.24M EUR 20-F · filed 2018-03-28 |